Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece.

Fragoulakis V, Kourlaba G, Maniadakis N.

Clinicoecon Outcomes Res. 2012;4:135-43. doi: 10.2147/CEOR.S31376. Epub 2012 May 29.

2.

Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events.

Gandhi SK, Jensen MM, Fox KM, Smolen L, Olsson AG, Paulsson T.

Clinicoecon Outcomes Res. 2012;4:1-11. doi: 10.2147/CEOR.S26621. Epub 2012 Jan 10.

3.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

4.

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.

Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S.

Clin Ther. 2008 Jul;30(7):1345-57.

PMID:
18691996
5.

Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal.

Pinto CG, Carrageta MO, Miguel LS.

Value Health. 2008 Mar-Apr;11(2):154-9. doi: 10.1111/j.1524-4733.2007.00224.x.

6.
7.

Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.

Peura P, Martikainen J, Soini E, Hallinen T, Niskanen L.

Curr Med Res Opin. 2008 Jun;24(6):1823-32. doi: 10.1185/03007990802144705. Epub 2008 May 15.

PMID:
18485270
8.

Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.

Montouchet C, Ruff L, Balu S.

J Med Econ. 2013 Jul;16(7):907-16. doi: 10.3111/13696998.2013.801350. Epub 2013 May 23.

PMID:
23641809
9.

[Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain].

Cosin Sales J, Fuentes Jiménez FJ, Mantilla Morató T, Ruiz E, Becerra V, Aceituno S, Ferrario MG, Lizán L, Gracia A.

Clin Investig Arterioscler. 2015 Sep-Oct;27(5):228-38. doi: 10.1016/j.arteri.2014.11.003. Epub 2015 Jan 29. Spanish.

PMID:
25640158
10.

Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.

Laires PA, Ejzykowicz F, Hsu TY, Ambegaonkar B, Davies G.

J Med Econ. 2015;18(8):565-72. doi: 10.3111/13696998.2015.1031794. Epub 2015 Apr 10.

PMID:
25788039
11.

Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation.

Ara R, Pandor A, Stevens J, Rees A, Rafia R.

Health Technol Assess. 2009 Jul;13(34):1-74, 75-118. doi: 10.3310/hta13340. Review.

12.

Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.

Kourlaba G, Fragoulakis V, Maniadakis N.

Appl Health Econ Health Policy. 2012 Jul 1;10(4):261-71. doi: 10.2165/11633820-000000000-00000.

PMID:
22667992
16.
17.

Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.

Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM.

Am J Manag Care. 2006 Nov;12(15 Suppl):S412-23.

18.

Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.

Kourlaba G, Fragoulakis V, Maniadakis N.

Appl Health Econ Health Policy. 2012 Sep 1;10(5):331-42. doi: 10.2165/11633970-000000000-00000.

PMID:
22853743
19.

Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.

Cao X, Ejzykowicz F, Ramey DR, Sajjan S, Ambegaonkar BM, Mavros P, Tunceli K.

Clin Ther. 2015 Apr 1;37(4):804-15. doi: 10.1016/j.clinthera.2014.12.019. Epub 2015 Jan 24.

PMID:
25626487
20.

A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.

Tárraga-López PJ, Celada-Rodríguez A, Cerdán-Oliver M, Solera-Albero J, Ocaña-López JM, López-Cara MA, De Miguel-Clave J.

Pharmacoeconomics. 2005;23(3):275-87. Erratum in: Pharmacoeconomics. 2006;24(1):106.

PMID:
15836008

Supplemental Content

Support Center